Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
02:15pm, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Co
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
12:45pm, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
12:15pm, Tuesday, 11'th Jun 2024
LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Comp
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
06:55am, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!
05:00am, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Bi
Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
05:45pm, Monday, 10'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
05:32pm, Monday, 10'th Jun 2024
LOS ANGELES , June 10, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agains
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB
01:00pm, Monday, 10'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)? Did you purchase your shares between February 3, 2022 and February 13,
Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
11:35am, Monday, 10'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
10:55am, Monday, 10'th Jun 2024
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
